Research & Literature

PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.

Morais CL, Herawi M, Toubaji A, et al.

The Prostate 2015; (75(14)):1610-9 doi:10.1002/pros.23042.

No Detrimental Effect of a Positive Family History on Long-Term Outcomes Following Radical Prostatectomy.

Brath JM, Grill S, Ankerst DP, et al.

The Journal of urology 2016; (195(2)):343-8.

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.

Desmond A, Kurian AW, Gabree M, et al.

JAMA oncology 2015; (1(7)):943-51 doi:10.1001/jamaoncol.2015.2690.

Multiparametric magnetic resonance imaging: Current role in prostate cancer management.

Ueno Y, Tamada T, Bist V, et al.

International journal of urology : official journal of the Japanese Urological Association 2016; (23(7)):550-7 doi:10.1111/iju.13119.

Association between germline homeobox B13 (HOXB13) G84E allele and prostate cancer susceptibility: a meta-analysis and trial sequential analysis.

Zhang J, Xiao L, Qin Z, et al.

Oncotarget 2016; (7(41)):67101-67110 doi:10.18632/oncotarget.11937.

Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.

Na R, Zheng SL, Han M, et al.

European urology 2017; (71(5)):740-747 doi:10.1016/j.eururo.2016.11.033.

Prostate Cancer Screening in a New Era of Genetics.

Cheng HH, Pritchard CC, Montgomery B, et al.

Clinical genitourinary cancer 2017; (15(6)):625-628 doi:10.1016/j.clgc.2017.05.024.

Inherited Predisposition to Prostate Cancer: From Gene Discovery to Clinical Impact.

Cooney KA

Transactions of the American Clinical and Climatological Association 2017; (128()):14-23.

Unfavorable Pathology, Tissue Biomarkers and Genomic Tests With Clinical Implications in Prostate Cancer Management.

Nguyen JK, Magi-Galluzzi C

Advances in anatomic pathology 2018; (25(5)):293-303 doi:10.1097/PAP.0000000000000192.

Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.

Brown LC, Ahmed HU, Faria R, et al.

Health technology assessment (Winchester, England) 2018; (22(39)):1-176 doi:10.3310/hta22390.

Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.

Carter HB, Helfand B, Mamawala M, et al.

European urology 2019; (75(5)):743-749 doi:10.1016/j.eururo.2018.09.021.

Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.

Nicolosi P, Ledet E, Yang S, et al.

JAMA oncology 2019; (5(4)):523-528 doi:10.1001/jamaoncol.2018.6760.

Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.

Gandaglia G, Albers P, Abrahamsson PA, et al.

European urology 2019; (76(2)):142-150 doi:10.1016/j.eururo.2019.04.033.

Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: updated recommendations from the International Collaboration on Cancer Reporting.

Kench JG, Judge M, Delahunt B, et al.

Virchows Archiv : an international journal of pathology 2019; (475(3)):263-277 doi:10.1007/s00428-019-02574-0.

Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.

Nyberg T, Frost D, Barrowdale D, et al.

European urology 2020; (77(1)):24-35 doi:10.1016/j.eururo.2019.08.025.

Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.

Page EC, Bancroft EK, Brook MN, et al.

European urology 2019; (76(6)):831-842 doi:10.1016/j.eururo.2019.08.019.

TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).

Hofman MS, Emmett L, Violet J, et al.

BJU international 2019; (124 Suppl 1()):5-13 doi:10.1111/bju.14876.

Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: a case report.

Hongo H, Kosaka T, Aimono E, et al.

Diagnostic pathology 2020; (15(1)):5 doi:10.1186/s13000-019-0916-z.

Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer.

Wei Y, Wu J, Gu W, et al.

The oncologist 2020; (25(7)):e1042-e1050 doi:10.1634/theoncologist.2019-0495.

Intraductal carcinoma of the prostate.

Szentirmai E, Giannico GA

Pathologica 2020; (112(1)):17-24 doi:10.32074/1591-951X-5-20.

Olaparib for Metastatic Castration-Resistant Prostate Cancer.

de Bono J, Mateo J, Fizazi K, et al.

The New England journal of medicine 2020; (382(22)):2091-2102 doi:10.1056/NEJMoa1911440.

Diagnosing hereditary cancer predisposition in men with prostate cancer.

Pritzlaff M, Tian Y, Reineke P, et al.

Genetics in medicine : official journal of the American College of Medical Genetics 2020; (22(9)):1517-1523 doi:10.1038/s41436-020-0830-5.

The presence of intraductal carcinoma of the prostate is closely associated with poor prognosis: a systematic review and meta-analysis.

Zhang YC, Sun GL, Ma DL, et al.

Asian journal of andrology 2021; (23(1)):103-108 doi:10.4103/aja.aja_21_20.

The 2019 International Society of Urological Pathology Consensus Conference on Prostate Cancer Grading.

van Leenders GJLH, van der Kwast TH, Iczkowski KA

European urology 2021; (79(6)):707-709 doi:10.1016/j.eururo.2020.08.004.

Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome.

Yadav S, Hart SN, Hu C, et al.

JCO precision oncology 2019; (3()) doi:10.1200/PO.19.00067.

Pathogenic Germline DNA Repair Gene and HOXB13 Mutations in Men With Metastatic Prostate Cancer.

Boyle JL, Hahn AW, Kapron AL, et al.

JCO precision oncology 2020; (4()) doi:10.1200/PO.19.00284.

No detrimental effect of a positive family history on postoperative upgrading and upstaging in men with low risk and favourable intermediate-risk prostate cancer: implications for active surveillance.

Herkommer K, Maier N, Ankerst DP, et al.

World journal of urology 2021; (39(7)):2499-2506 doi:10.1007/s00345-020-03485-5.

Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study.

Karlsson Q, Brook MN, Dadaev T, et al.

European urology oncology 2021; (4(4)):570-579 doi:10.1016/j.euo.2020.12.001.

Genetic predisposition to prostate cancer: an update.

Ni Raghallaigh H, Eeles R

Familial cancer 2022; (21(1)):101-114 doi:10.1007/s10689-021-00227-3.

Impact of family history on oncological outcomes in primary therapy for localized prostate cancer patients: a systematic review and meta-analysis.

Urabe F, Kimura S, Yamamoto S, et al.

Prostate cancer and prostatic diseases 2021; (24(3)):638-646 doi:10.1038/s41391-021-00329-0.

Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.

Lozano R, Salles DC, Sandhu S, et al.

European journal of cancer (Oxford, England : 1990) 2021; (147()):74-83 doi:10.1016/j.ejca.2021.01.027.

[Familial prostate cancer and genetic predisposition].

Meissner VH, Jahnen M, Herkommer K

Der Urologe. Ausg. A 2021; (60(5)):567-575 doi:10.1007/s00120-021-01491-y.

Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention.

Vietri MT, D'Elia G, Caliendo G, et al.

International journal of molecular sciences 2021; (22(7)) doi:10.3390/ijms22073753.

First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletion.

Shojo K, Kosaka T, Nakamura K, et al.

IJU case reports 2021; (4(3)):176-179 doi:10.1002/iju5.12274.

ISUP Consensus Definition of Cribriform Pattern Prostate Cancer.

van der Kwast TH, van Leenders GJ, Berney DM, et al.

The American journal of surgical pathology 2021; (45(8)):1118-1126 doi:10.1097/PAS.0000000000001728.

Diverse immune response of DNA damage repair-deficient tumors.

Qing T, Jun T, Lindblad KE, et al.

Cell reports. Medicine 2021; (2(5)):100276 doi:10.1016/j.xcrm.2021.100276.

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Sartor O, de Bono J, Chi KN, et al.

The New England journal of medicine 2021; (385(12)):1091-1103 doi:10.1056/NEJMoa2107322.

Genetically Informed Prostate Cancer Screening.

Arcot R, Morgan TM, Polascik TJ

The Urologic clinics of North America 2021; (48(3)):373-386 doi:10.1016/j.ucl.2021.04.001.

Intraductal Carcinoma of the Prostate: Extreme Nuclear Size Is Not a Diagnostic Parameter.

Samaratunga H, Delahunt B, Yaxley JW, et al.

The American journal of surgical pathology 2021; (45(11)):1527-1533 doi:10.1097/PAS.0000000000001776.

Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021.

Van Poppel H, Roobol MJ, Chapple CR, et al.

European urology 2021; (80(6)):703-711 doi:10.1016/j.eururo.2021.07.024.

Epidemiology and Prevention of Prostate Cancer.

Gandaglia G, Leni R, Bray F, et al.

European urology oncology 2021; (4(6)):877-892 doi:10.1016/j.euo.2021.09.006.

Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin.

Lindh C, Samaratunga H, Delahunt B, et al.

The Prostate 2022; (82(5)):576-583 doi:10.1002/pros.24304.

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.

Smith MR, Scher HI, Sandhu S, et al.

The Lancet. Oncology 2022; (23(3)):362-373 doi:10.1016/S1470-2045(21)00757-9.

Current conundrums with cribriform prostate cancer.

Gordetsky JB, Schaffer K, Hurley PJ

Histopathology 2022; (80(7)):1038-1040 doi:10.1111/his.14665.

Editorial Comment from Dr. Urabe to Impact of family history on clinicopathological variables and disease progression in Japanese prostate cancer patients undergoing robotic-assisted radical prostatectomy.

Urabe F

International journal of urology : official journal of the Japanese Urological Association 2022; (29(11)):1346-1347 doi:10.1111/iju.15011.

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage Signatures.

McNevin CS, Cadoo K, Baird AM, et al.

Cancers 2022; (14(19)) doi:10.3390/cancers14194751.

PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study.

Du XX, Dong YH, Zhu HJ, et al.

Asian journal of andrology 2023; (25(2)):179-183 doi:10.4103/aja2022102.

Cribriform pattern and intraductal carcinoma of the prostate can have a clinicopathological impact, regardless of their percentage and/or number of cores.

Okubo Y, Sato S, Hasegawa C, et al.

Human pathology 2023; (135()):99-107 doi:10.1016/j.humpath.2023.01.008.

Rucaparib or Physician's Choice in Metastatic Prostate Cancer.

Fizazi K, Piulats JM, Reaume MN, et al.

The New England journal of medicine 2023; (388(8)):719-732 doi:10.1056/NEJMoa2214676.

PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials.

Ramnaraign B, Sartor O

The oncologist 2023; (28(5)):392-401 doi:10.1093/oncolo/oyac279.

Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy.

Wei JT, Barocas D, Carlsson S, et al.

The Journal of urology 2023; (210(1)):54-63 doi:10.1097/JU.0000000000003492.

Guidelines for genetic testing in prostate cancer: a scoping review.

Tuffaha H, Edmunds K, Fairbairn D, et al.

Prostate cancer and prostatic diseases 2024; (27(4)):594-603 doi:10.1038/s41391-023-00676-0.

PSMA-617 inhibits proliferation and potentiates the 177Lu-PSMA-617-induced death of human prostate cancer cells.

Zhao Y, Culman J, Cascorbi I, et al.

Naunyn-Schmiedeberg's archives of pharmacology 2023; (396(11)):3315-3326 doi:10.1007/s00210-023-02539-w.

Impact of DNA damage repair alterations on prostate cancer progression and metastasis.

Lukashchuk N, Barnicle A, Adelman CA, et al.

Frontiers in oncology 2023; (13()):1162644 doi:10.3389/fonc.2023.1162644.

FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.

Fallah J, Xu J, Weinstock C, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024; (42(5)):605-613 doi:10.1200/JCO.23.01868.

The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer.

Teppala S, Scuffham PA, Tuffaha H

International journal of technology assessment in health care 2024; (40(1)):e14 doi:10.1017/S0266462324000011.

Magnetic Resonance Imaging-based Prostate Cancer Screening in Carriers of Pathogenic Germline Mutations: Interim Results from the Initial Screening Round of the Prostate Cancer Genetic Risk Evaluation and Screening Study.

Amini AE, Hunter AE, Almashad A, et al.

European urology oncology 2024; (7(6)):1358-1366 doi:10.1016/j.euo.2024.01.015.

Intraductal Carcinoma of the Prostate versus Simulants: A Differential Diagnosis Growing in Clinical Impact.

Smith SC, Wobker SE

Cancers 2024; (16(6)) doi:10.3390/cancers16061097.

Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial.

Saad F, Armstrong AJ, Oya M, et al.

European urology oncology 2024; (7(6)):1394-1402 doi:10.1016/j.euo.2024.03.006.

Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.

Newcomb LF, Schenk JM, Zheng Y, et al.

JAMA 2024; (331(24)):2084-2093 doi:10.1001/jama.2024.6695.

Screening guidelines for individuals at increased risk for prostate cancer.

Lorentz J, Woollcombe J, Loblaw A, et al.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2024; (18(10)):E301-E307 doi:10.5489/cuaj.8710.

Impact of family history of prostate cancer on disease progression for prostatic cancer patients undergoing active surveillance: A systematic review and meta-analysis.

Jeon J, Kim JH, Ha JS, et al.

Investigative and clinical urology 2024; (65(4)):315-325 doi:10.4111/icu.20240053.

A systematic review of family history, race/ethnicity, and genetic risk on prostate cancer detection and outcomes: Considerations in PSA-based screening.

Graham NJ, Souter LH, Salami SS

Urologic oncology 2025; (43(1)):29-40 doi:10.1016/j.urolonc.2024.06.002.

BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review.

Cheng HH, Shevach JW, Castro E, et al.

JAMA oncology 2024; (10(9)):1272-1281 doi:10.1001/jamaoncol.2024.2185.

Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer.

Eapen RS, Williams SG, Macdonald S, et al.

Nature reviews. Urology 2024; (21(11)):676-686 doi:10.1038/s41585-024-00913-8.

Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project.

Shiota M, Matsubara N, Kato T, et al.

BJC reports 2024; (2(1)):28 doi:10.1038/s44276-024-00049-7.

French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Management of metastatic disease and castration resistance.

Ploussard G, Dariane C, Mathieu R, et al.

The French journal of urology 2024; (34(12)):102710 doi:10.1016/j.fjurol.2024.102710.

Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.

Shore N, Nielsen SM, Esplin ED, et al.

JCO oncology practice 2025; (21(6)):747-753 doi:10.1200/OP-24-00626.

First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.

Matsubara N, Azad AA, Agarwal N, et al.

The Lancet. Oncology 2025; (26(4)):470-480 doi:10.1016/S1470-2045(25)00030-0.

Advances in Targeted Therapy for Metastatic Prostate Cancer.

Grewal K, Dorff TB, Mukhida SS, et al.

Current treatment options in oncology 2025; (26(6)):465-475 doi:10.1007/s11864-025-01323-7.

Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.

Fizazi K, Azad AA, Matsubara N, et al.

Lancet (London, England) 2025; (406(10502)):461-474 doi:10.1016/S0140-6736(25)00683-X.

Association of HOXB13 G84E With Prostate Cancer Among 592,158 Men.

Crawford TB, Nelson T, Karunamuni R, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2025; (23(10)).

Clinical translation of polygenic scores for prostate cancer screening.

Ratner D, Vassy JL

Nature reviews. Urology 2026; (23(4)):256-265 doi:10.1038/s41585-025-01095-7.

Precision Care for Hereditary Urologic Cancers: Genetic Testing, Counseling, Surveillance, and Therapeutic Implications.

Somoto T, Utsumi T, Ikeda R, et al.

Current oncology (Toronto, Ont.) 2025; (32(12)) doi:10.3390/curroncol32120698.

Genetic Testing and Imaging in Men with Familial History or Genetic Predisposition of Prostate Cancer-Introducing the Prospective "ProFam-Risk" Study.

Lakes J, Boschheidgen M, Antoch G, et al.

European urology open science 2026; (84()):13-21 doi:10.1016/j.euros.2025.12.018.

SOGUG Multidisciplinary Expert Panel Consensus on Updated Diagnosis and Characterization of Prostate Cancer Patients.

Gallardo E, Gómez-de-Iturriaga A, Muñoz-Rodríguez J, et al.

Current oncology (Toronto, Ont.) 2026; (33(1)) doi:10.3390/curroncol33010061.